AuntMinnie

MARCH 26, 2024

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JUNE 20, 2024

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

MAY 31, 2023

Flavio Forrer , MD, PhD, Chairman of Nuclear Medicine in the Division of Radiology and Nuclear Medicine at Kantonsspital St. Measurement follows NEMA NU 2-2018. [v] v] Up to 53% reduction of PET scan time on Omni Legend 32 cm compared to Discovery MI 25 cm, as demonstrated in phantom testing. [vi]

Nuclear Medicine 98

Nuclear Medicine Healthcare Healthcare IT 98

Imaging Technology

JUNE 15, 2023

Ken Herrmann , Section Editor of the Journal of Nuclear Medicine , said: “The clinical translation of a fluorine-18 PET tracer that targets CD8 would be a significant breakthrough in the field, not just for patients but also in the world of drug development.” Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,

Radiopharmaceuticals 98

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 98